Latest Women's Health News


FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer

FDA Approves Trodelvy for Metastatic Triple-Negative Breast CancerTHURSDAY, April 23, 2020 (HealthDay News) -- Accelerated approval has been granted to Trodelvy (sacituzumab govitecan-hziy) to treat patients with metastatic triple-negative breast cancer who have received at least two previous therapies, the U.S. Food and Drug Administration announced Wednesday. Approval of Trodelvy, a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, was based on clinical trial data from 108 breast cancer patients with metastatic triple-negative disease. Researchers found an overall response rate of 33.3 percent and a median response duration of 7.7 months. Response was maintained for six months or longer in 55.6 percent of patients who responded, and 16.7 percent of those who responded maintained response for one year or longer. A Boxed Warning...

Interventions Boost Abstinence, Condom Use Among Black...

22 April 2020
Interventions Boost Abstinence, Condom Use Among Black Teens: StudyWEDNESDAY, April 22, 2020 (HealthDay News) -- Sexual health programs appear to help increase condom use and abstinence among black American teens, researchers say. They analyzed data from 29 studies that examined the effect of school- and community-based programs on nearly 12,000 teens. "We focused on black adolescents because they face greater health disparities when it comes to the risk of unplanned pregnancy and contracting sexually transmitted infections (STIs) compared to other adolescents," said first author Reina Evans, a doctoral student at North Carolina State University. She said the disparity stems largely from the context in which black teens make decisions about their health. "For example, stress from racism and discrimination, as well as unequal access to health care...

Rural Women at Higher Risk of Early Death From Heart Disease

22 April 2020
Rural Women at Higher Risk of Early Death From Heart DiseaseWEDNESDAY, April 22, 2020 (HealthDay News) -- Women under age 65 with coronary artery disease are more likely to die if they live in rural areas of the United States, and premature deaths among them have surged, a new study finds. Researchers analyzed nationwide data on premature deaths from coronary artery disease between 1999 and 2017. While premature deaths decreased overall, they remained consistently higher in rural areas -- regardless of sex, race or age group. Roughly 20% of Americans live in rural areas. Deaths have not risen among men overall, but the rate in those 55 to 64 stopped improving in small to medium towns in 2011, and in rural areas in 2008, the study found. In rural areas, death rates due to coronary artery disease rose 11.2% for 55- to 64-year-old women...

Many Adults Delay Getting Help for Eating Disorders

21 April 2020
Many Adults Delay Getting Help for Eating DisordersTUESDAY, April 21, 2020 (HealthDay News) -- Young adults may be waiting too long to seek help for eating disorders, a new study suggests. Researchers surveyed 300 young adults, ages 18-25, in Australia. They found the majority had eating, weight or body shape concerns. "Concerningly, only a minority of people with eating disorder symptoms had sought professional help and few believed they needed help despite the problems they were experiencing," said study co-author Dan Fassnacht. He's a psychology lecturer at Flinders University in Adelaide, South Australia. Reasons for not getting professional care include denial, concerns about losing control of their eating or weight, and not understanding the severity of their eating disorder. Feeling embarrassed or fearing that others don't...

Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast Cancer

20 April 2020
Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast CancerMONDAY, April 20, 2020 (HealthDay News) -- The U.S. Food and Drug Administration announced Friday the approval of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Tukysa, a kinase inhibitor, is indicated for patients who have already received treatment with at least one anti-HER2-based regimen in the metastatic setting. Approval was based on results of the HER2CLIMB clinical trial, which enrolled 612 patients with HER2-positive advanced unresectable or metastatic breast cancer who had previously received treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). Forty-eight percent of patients had brain metastases at trial...

Copyright © 2018 HealthDay. All rights reserved.